Anti-Infectives Restore ORKAMBI<sup>®</sup> Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of <i>P. aeruginosa</i>
Chronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI<sup>®</sup> (Lumacaftor-Ivacaftor) is an approved combination therapy for Cystic Fibrosis (CF) patients bearing the most common mutation, F508del, in th...
Main Authors: | Onofrio Laselva, Tracy A. Stone, Christine E. Bear, Charles M. Deber |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/10/2/334 |
Similar Items
-
Functional rescue of F508del-CFTR using small molecule correctors
by: Steven eMolinski, et al.
Published: (2012-09-01) -
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors
by: Giada Righetti, et al.
Published: (2020-10-01) -
Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator Therapies
by: Martina Gentzsch, et al.
Published: (2021-03-01) -
Treatment of Cystic Fibrosis Patients Homozygous for <i>F508del</i> with Lumacaftor-Ivacaftor (Orkambi<sup>®</sup>) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
by: Maria Favia, et al.
Published: (2020-03-01) -
Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA<sup>TM</sup>
by: Onofrio Laselva, et al.
Published: (2021-04-01)